Food News and Research

RSS

FDA approves Clinical Data's Viibryd for major depressive disorder

Clinical Data, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD).

24 Jan 2011

Global Poverty Summit addresses MDGs, global trade policy

At the Global Poverty Summit January 16-19 in Johannesburg, South Africa, "academics, policy-makers, civil society activists and development workers ... agreed that the [U.N. Millennium Development Goals] MDGs have made a difference, but have fallen far short of the ambitious targets on poverty, education, health, gender equality and global partnership that 189 countries committed to achieving by 2015," IRIN reports.

24 Jan 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

New research shows how humans readily learn to throw long distances

Can't help molding some snow into a ball and hurling it or tossing a stone as far into a lake as you can? New research from Indiana University and the University of Wyoming shows how humans, unlike any other species on Earth, readily learn to throw long distances. This research also suggests that this unique evolutionary trait is entangled with language development in a way critical to our very existence.

24 Jan 2011

SuppreMol completes successful pre-IND meeting with U.S. FDA

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound SM101, which is being developed for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).

24 Jan 2011

Eliminating sugary drinks from diet can reduce tooth decay in American Indian children

A study conducted in four American Indian communities in the Pacific Northwest presents an effective strategy to convince mothers to switch young children from drinking sweetened soda to water and shows that eliminating these sugary drinks from the diets of the youngest members of the tribe significantly decreased tooth decay.

24 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

Two studies explore relationship between nutrition and asthma

Asthma is one of the world's most common chronic diseases, affecting as many as 300 million people. It is estimated that by 2025 there could be an additional 100 million people with the disease. This rapid increase in asthma is most likely due to changing environmental or lifestyle factors, and over the last 15 years, changing diet has emerged as a promising contributor. Two studies published in the in the February 2011 issue of the Journal of the American Dietetic Association explore the possible relationship between nutrition and asthma.

24 Jan 2011

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults.

24 Jan 2011

CHIL receives $23.7 NIFA grant to prevent young child obesity

The Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region recently received $23.7 in funding from the USDA National Institute for Food and Agriculture.

24 Jan 2011

Environmental contaminant levels in mother's body decrease during breast-feeding: Study

The levels of environmental contaminants in a mother's body decrease during breast-feeding. After a year of lactation, the levels of a number of environmental contaminants in breast milk drop by 15 - 94 per cent, according to a recent study from the Norwegian Institute of Public Health. There has been little study into this topic previously.

24 Jan 2011

FDA approves On-X AAP with Vascutek Gelweave Valsalva Graft

On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.

23 Jan 2011

Kaiser Permanente's 2010 charitable contributions top $35 million

Kaiser Permanente of the Mid-Atlantic States, the area's largest not-for-profit health plan and care provider, announced today that its 2010 charitable contributions topped $35 million. Approximately $25 million was used for direct medical care and insurance coverage for uninsured and underserved residents of Maryland, Virginia, and the District of Columbia, and another $10 million in grants, donations, and sponsorships went to organizations that support the health of the region.

21 Jan 2011

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

CureFAKtor Pharmaceuticals, LLC, a privately-held biopharmaceutical company focused on the research and development of Focal Adhesion Kinase (FAK) inhibitors for cancer, today presented research results at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco demonstrating that novel FAK inhibitors targeting the binding site of vascular endothelial growth factor receptor 3 (VEGFR-3) reduced the growth of pancreatic cancer cells in vitro and in vivo.

21 Jan 2011

Researchers reveal how genetic mutation contributes to cancer development

Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation's discovery in 2008. The hunt is now yielding fruit. In the Jan. 18, 2011 issue of Cancer Cell, researchers reveal how the mutation contributes to cancer development and suggest potential ways to counter its effects.

21 Jan 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

NewLink Genetics Corporation today announced that additional data from its Phase 2 clinical trial of the company's investigational HyperAcute® Pancreas cancer immunotherapy will be presented during a poster session at the American Society of Clinical Oncology 2011 Gastrointestinal Cancers Symposium in San Francisco, California.

21 Jan 2011

SQI fourth quarter net loss increases to $2,621,000

SQI Diagnostics Inc., a medical systems automation company focused on evolving laboratory-based autoimmune biomarker testing, today announced its financial and operational results for the fourth quarter and year ended September 30, 2010.

21 Jan 2011

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Intellipharmaceutics International Inc. today announced that it has received purchase agreement commitments from institutional investors to provide the Company with approximately US$12,000,000 in gross proceeds through the sale of its common stock and warrants.

21 Jan 2011

Three million Medicare beneficiaries receive prescription drug cost relief through Affordable Care Act

U.S. Department of Health and Human Services Secretary Kathleen Sebelius today announced that three million Medicare beneficiaries nationwide have received prescription drug cost relief through the Affordable Care Act. To date, three million eligible beneficiaries who fell into the drug coverage gap known as the donut hole during 2010 have been mailed a one-time, tax-free $250 rebate check.

21 Jan 2011

Food News and Research

FDA approves Clinical Data's Viibryd for major depressive disorder

Global Poverty Summit addresses MDGs, global trade policy

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

New research shows how humans readily learn to throw long distances

SuppreMol completes successful pre-IND meeting with U.S. FDA

Eliminating sugary drinks from diet can reduce tooth decay in American Indian children

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

Two studies explore relationship between nutrition and asthma

PGxHealth receives FDA approval for Viibryd tablets to treat major depressive disorder

CHIL receives $23.7 NIFA grant to prevent young child obesity

Environmental contaminant levels in mother's body decrease during breast-feeding: Study

FDA approves On-X AAP with Vascutek Gelweave Valsalva Graft

Kaiser Permanente's 2010 charitable contributions top $35 million

Novel FAK inhibitors targeting binding site of VEGFR-3 reduce growth of pancreatic cancer cells

Researchers reveal how genetic mutation contributes to cancer development

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

Additional data from HyperAcute Pancreas cancer immunotherapy Phase 2 trial to be presented at ASCO 2011

SQI fourth quarter net loss increases to $2,621,000

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Three million Medicare beneficiaries receive prescription drug cost relief through Affordable Care Act

The future is bioengineered: Synthetic biology and global sustainability eBook

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Latest News